BCRX (STOCKS)
BioCryst Pharmaceuticals Inc
$9.806900
-0.783100 (-7.39%)
Prev close: $10.590000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Charles K. Gayer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,013.28M
- Employees
- 580
- P/E (TTM)
- -7.04
- P/B (TTM)
- -5.95
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $940.61M |
| Benefits Costs and Expenses | $1.32B |
| Cost Of Revenue | $20.93M |
| Costs And Expenses | $1.25B |
| Gross Profit | $919.69M |
| Nonoperating Income/Loss | -$68.03M |
| Operating Expenses | $1.23B |
| Selling, General, and Administrative Expenses | $337.33M |
| Research and Development | $197.76M |
| Operating Income/Loss | -$313.16M |
| Income/Loss From Continuing Operations After Tax | -$384.67M |
| Income/Loss From Continuing Operations Before Tax | -$381.19M |
| Income Tax Expense/Benefit | $3.49M |
| Net Income/Loss | -$384.67M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$384.67M |
| Net Income/Loss Available To Common Stockholders, Basic | -$384.67M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.36 |
| Diluted Earnings Per Share | -$1.49 |
| Basic Average Shares | 707,277,000 |
| Diluted Average Shares | 727,540,000 |
| Assets | $557.85M |
| Current Assets | $484.68M |
| Inventory | $6.06M |
| Other Current Assets | $478.63M |
| Noncurrent Assets | $73.17M |
| Fixed Assets | $9.06M |
| Other Non-current Assets | $64.11M |
| Liabilities | $1.01B |
| Current Liabilities | $208.85M |
| Accounts Payable | $11.46M |
| Other Current Liabilities | $197.39M |
| Noncurrent Liabilities | $803.29M |
| Equity | -$454.29M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$454.29M |
| Liabilities And Equity | $557.85M |
| Net Cash Flow From Operating Activities | $376.14M |
| Net Cash Flow From Operating Activities, Continuing | $376.14M |
| Net Cash Flow From Investing Activities | -$448.71M |
| Net Cash Flow From Investing Activities, Continuing | -$448.71M |
| Net Cash Flow From Financing Activities | $124.63M |
| Net Cash Flow From Financing Activities, Continuing | $124.63M |
| Exchange Gains/Losses | -$647.00K |
| Net Cash Flow | $51.40M |
| Net Cash Flow, Continuing | $52.05M |
| Comprehensive Income/Loss | -$386.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$386.85M |
| Other Comprehensive Income/Loss | $335.37M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.17M |